Gratis Berlangganan

Tuliskan Alamat Email Anda. Gratis!

Delivered by FeedBurner

Two Phases of C-Peptide Decline Identified in Type I Diabetes

Posted by On 6:47 PM

Two Phases of C-Peptide Decline Identified in Type I Diabetes

Roxanne Nelson, BSN, RN July 11, 2018 Two Phases of C-Peptide Decline Identified in Type I Diabetes Share this content:

  • facebook
  • twitter
  • linkedin
  • google
Investigators identified 2 phases of C-peptide decline, the initial exponential fall and a stable period that follows.
Investigators identified 2 phases of C-peptide decline, the in itial exponential fall and a stable period that follows.

There are 2 phases of C-peptide decline that occur during the first 4 decades following a diagnosis of type 1 diabetes (T1D), and further understanding of the pathophysiologic and immunologic differences between these two phases may help increase knowledge of β-cell survival, according to a study published in Diabetes Care.

The decline in C-peptide during the first 5 years following the diagnosis of T1D has been well studied, but much less is known about long-term sequelae. In this study, the investigators evaluated the trajectory of C-peptide levels in a large cohort of 1549 patients up to 40 years after receiving a diagnosis of T1D. The cross-sectional study assessed the pattern of association between urinary C-peptide/creatinine ratio (UCPCR) and duration of diabetes using nonlinear regression approaches, and then the investigators replicated their results in longitudinal follow-up data for b oth UCPCR (n=161 individuals, 326 observations) and plasma C-peptide (n=93 individuals, 473 observations).

Continue Reading Below

In the cohort, 2 clear phases of C-peptide decline were identified. The first decline occurred over a 7-year period (47% decrease/year [95% CI, âˆ'51% to âˆ'43%]) and that was followed by a period of stability (+0.07%/year [âˆ'1.3 to +1.5]). The durations and slopes in patients above and below the median age at diagnosis (10.8) were similar in both phases, but levels were lower in younger patients irrespective of duration. Patterns also remained consistent for both longitudinal UCPCR (n=162; ≤7 years duration: âˆ'48%/year [âˆ'55% to âˆ'38%]; >7 years duration âˆ'0.1% [âˆ'4.1% to +3.9%]) and plasma C-peptide (n=93; >7 years duration only: âˆ'2.6% [âˆ'6.7% to +1.5%]).

Related Articles
  • Technosphere Inhaled Insulin Improves Glycemic Control in Type 1 Diabetes
  • Safety and Performan ce of Omnipod HCL for Children With Type 1 Diabetes
  • Most Teens, Young Adults With Type 1 Diabetes Report Stigma

The investigators note that the stabilization of C-peptide levels 7 years after diagnosis “suggests that there are important and previously unrecognized changes in immune function and/or β-cell viability around this time that may have critical implications for future pharmaceutical interventions.”


Shields BM, McDonald TJ, Oram R, et al; TIGI Consortium. C-peptide decline in type 1 diabetes has two phases: An initial exponential fall and a subsequent stable phase [published online Jun 7, 2018]. Diabetes Care. doi:10.2337/dc18-0465

Recommended for you Related Topics
  • Diabetes
  • Type 1 Diabetes

Endocrinology Advisor Articles

  • Intensifying Treatment Does Not Negatively Affect Type 2 Diabetes
  • Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
  • Two Phases of C-Peptide Decline Identified in Type I Diabetes
  • Midluteal Progesterone May Be a Marker for Fertility Treatment Outcomes
  • Romosozumab: Effective in Men With Osteoporosis
  • Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
  • First CGM System With Implantable Glucose Sensor Approved
  • Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
  • Risk for Below Knee Amputations With Ca nagliflozin vs Other Antihyperglycemic Agents
  • Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
  • NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
  • Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
  • Link Between Oral Diabetes Medications and Bullous Pemphigoid
  • Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
  • β-Cell Function in Youth With Impaired Glucose Tolerance, T2D

Sign Up for Free e-Newsletters

CME Focus

Blocking TSH-Receptor Antibodies in Autoimmune Thyroid Disease

CME|CE 4.00 Credits

Case 3 - A 19-Year-Old Latina College Student with Prediabetes

CME|CE 1.25 Credits More myCME courses »Sumber: Google News | Liputan 24 Tigi

« Prev Post
Next Post »